About Hester Biosciences Limited
Data last updated: 28 January 2026
Hester Biosciences Limited is a public limited company based in Mahesana, Gujarat, India. It specialises in animal pharmaceuticals and healthcare, a part of the broader pharmaceuticals sector. Incorporated on 29 April 1987, the company has been in operation for over 39 years.
Registered with ROC Ahmedabad under CIN L99999GJ1994PTC022333. Listed on BSE: 524669 and NSE: HESTERBIO.
Capital: an authorised share capital of ₹11.2 Cr and a paid-up capital of ₹8.51 Cr. Formerly known as Hester Pharmaceuticals Limited and Hester Pharmaceuticals Private Limited. It is led by directors including Sanjiv Dinesh Gandhi and Bhupendra Vithaldas Gandhi.
Last AGM: 13 August 2025. Financial statements filed for year ended 31 March 2025. Office: Mahesana, Gujarat.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹332.6 Cr, a growth of 6.91% compared to the previous year. The net worth stands at ₹367.79 Cr (up 12.59% YoY). Total assets are valued at ₹677.94 Cr (up 3.76% YoY).
The company has a workforce of approximately 695 employees as per the latest available data.
The company is associated with 1 brand - Hester Biosciences. As per MCA filings, the company has open charges of ₹202.05 Cr and satisfied charges of ₹90.09 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website hester.in.
-
EmailLocked
-
TelephoneLocked
-
WebsiteLocked
-
Social Media
-
Registered AddressVillage Meda – Adraj, Taluka Kadi, Mahesana, Gujarat, India – 384441
-
IndustryPharma, Animal Pharmaceuticals & Healthcare
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Hester Biosciences Limited
Hester Biosciences Limited has undergone 2 name changes throughout its history. The company was previously known as Hester Pharmaceuticals Limited, and Hester Pharmaceuticals Private Limited. The current legal name is Hester Biosciences Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Hester Biosciences Limited | Current |
| Hester Pharmaceuticals Limited | Previous |
| Hester Pharmaceuticals Private Limited | Previous |
CIN History of Hester Biosciences Limited
Hester Biosciences Limited has one previous CIN (Corporate Identification Number): L99999GJ1994PTC022333. The current CIN is L99999GJ1987PLC022333, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L99999GJ1987PLC022333 | Current |
| L99999GJ1994PTC022333 | Previous |
Associated Brands with Hester Biosciences Limited
Hester Biosciences Limited operates one associated brand: Hester Biosciences. These brands represent Hester Biosciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of animal vaccines and healthcare products | hester.in |
Competitors & Alternatives of Hester Biosciences Limited
Brands and companies operating in the same space as Hester Biosciences Limited include Zoetis, Ceva, QBiotics and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
|
|
Animal medicines, vaccines, and diagnostics are manufactured and supplied. | Brussels, Belgium, Belgium | 2012 |
|
|
Animal health therapeutics are developed and supplied globally by Ceva. | Libourne, France, France | 1999 |
|
|
Small molecules from plant extracts are developed for medical applications. | Brisbane, Australia, Australia | 2000 |
|
|
Developer of monoclonal antibody therapeutics for pets | Babraham, United Kingdom, United Kingdom | 2017 |
|
|
Biopharmaceuticals for animals are manufactured and supplied through partnerships. | Liege, Belgium, Belgium | 2014 |
|
|
Veterinary antibodies for cats, dogs, and horses are developed. | Burlingame, United States, United States | 2012 |
|
|
Herpesvirus-based animal vaccines are developed against infectious diseases. | Plymouth, United Kingdom, United Kingdom | 2017 |
|
|
Proprietary microbiome technology is developed for companion and food animals. | Farmington, United States, United States | 2016 |
|
|
Protein-based biopharmaceuticals for animal disease treatment are developed. | Haidian, China, China | 2016 |
Business Activity of Hester Biosciences Limited
Hester Biosciences Limited is engaged in principal business activities including manufacturing and trade, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, wholesale trading. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details for Hester Biosciences Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Hester Biosciences Limited
Hester Biosciences Limited is audited by Chandulal M. Shah & Co. (ICAI peer reviewed, certificate valid till 2026-06-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Chandulal M. Shah & Co. (ICAI peer reviewed, certificate valid till 2026-06-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Hester Biosciences Limited
Hester Biosciences Limited is currently managed by 11 directors, with 16 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sanjiv Dinesh Gandhi | Director | 29 Apr 1987 | 39 Years 2 Months | Current |
|
Bhupendra Vithaldas Gandhi
Also directs:
Heritage Money Market Services Private Limited
|
Director | 21 Apr 2005 | 21 Years 2 Months | Current |
| Ravin Kanti Gandhi | Director | 22 Apr 1999 | 27 Years 2 Months | Current |
|
Rajiv Gandhi
Also directs:
Biolink Healthcare Limited, Hester Diagnostics Private Limited, Hester Coatings Llp and 5 more
|
Managing Director | 29 Apr 1987 | 39 Years 2 Months | Current |
|
Nina Rajiv Gandhi
Also directs:
Biolink Healthcare Limited, Hester Diagnostics Private Limited, Hester Coatings Llp and 2 more
|
Alternate Director | 07 May 2016 | 10 Years 2 Months | Current |
| Ashok Bhadakal Bhimarao | Director | 01 Apr 2020 | 6 Years 3 Months | Current |
Financials of Hester Biosciences Limited FY 2026 filings available
Hester Biosciences Limited reported revenue of ₹332.6 Cr (up 6.91% YoY) for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹332.6 Cr | ₹311.1 Cr | ₹304.55 Cr | ₹266.09 Cr | ₹235.01 Cr | ₹214.33 Cr | ₹183.27 Cr |
| Other Income | ₹9.68 Cr | ₹3.92 Cr | ₹10.64 Cr | ₹15.15 Cr | ₹13.74 Cr | ₹4.68 Cr | ₹6.37 Cr |
| Total Income | ₹342.28 Cr | ₹315.03 Cr | ₹315.18 Cr | ₹281.24 Cr | ₹248.75 Cr | ₹219.02 Cr | ₹189.63 Cr |
| Cost of Materials Consumed | ₹70.62 Cr | ₹63.95 Cr | ₹54.31 Cr | ₹52.99 Cr | ₹60.65 Cr | ₹38.66 Cr | ₹29.36 Cr |
| Purchases of Stock-in-Trade | ₹15.75 Cr | ₹17.6 Cr | ₹32.82 Cr | ₹29.75 Cr | ₹12.62 Cr | ₹7.97 Cr | ₹6.52 Cr |
| Changes in Inventories | -₹4.41 Cr | ₹6.78 Cr | ₹8.74 Cr | -₹5.25 Cr | -₹10.56 Cr | ₹3.6 Cr | -₹16.17 Cr |
| Employee Benefit Expense | ₹62.67 Cr | ₹62.42 Cr | ₹64.13 Cr | ₹56.02 Cr | ₹45.33 Cr | ₹38.92 Cr | ₹40.65 Cr |
| Finance Costs | ₹10.93 Cr | ₹12.7 Cr | ₹19.78 Cr | ₹9.32 Cr | ₹4.06 Cr | ₹6.6 Cr | ₹7.37 Cr |
| Depreciation & Amortisation | ₹18.88 Cr | ₹16.8 Cr | ₹17.17 Cr | ₹20.7 Cr | ₹16.58 Cr | ₹13.31 Cr | ₹13.07 Cr |
| Other Expenses | ₹101.32 Cr | ₹99.3 Cr | ₹90.88 Cr | ₹81.98 Cr | ₹66.98 Cr | ₹56.53 Cr | ₹67.51 Cr |
| Total Expenses | ₹275.76 Cr | ₹279.56 Cr | ₹287.84 Cr | ₹245.5 Cr | ₹195.67 Cr | ₹165.59 Cr | ₹148.31 Cr |
| Profit Before Exceptional Items & Tax | ₹66.53 Cr | ₹35.47 Cr | ₹27.34 Cr | ₹35.75 Cr | ₹53.08 Cr | ₹53.42 Cr | ₹41.33 Cr |
| Exceptional Items | ₹2.94 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹3.32 Cr | ₹0 |
| Profit Before Tax | ₹69.46 Cr | ₹35.47 Cr | ₹27.34 Cr | ₹35.75 Cr | ₹53.08 Cr | ₹50.1 Cr | ₹41.33 Cr |
| Total Tax Expense | ₹18.35 Cr | ₹10.75 Cr | ₹10.79 Cr | ₹12.12 Cr | ₹14.02 Cr | ₹15.41 Cr | ₹10.32 Cr |
| Net Profit | ₹57.48 Cr | ₹28.83 Cr | ₹21.17 Cr | ₹28.04 Cr | ₹39.48 Cr | ₹34.7 Cr | ₹31 Cr |
| attributable to Owners | ₹55.64 Cr | ₹27.49 Cr | ₹18.89 Cr | ₹26.63 Cr | ₹39.32 Cr | ₹34.43 Cr | ₹29.17 Cr |
| attributable to NCI | ₹1.85 Cr | ₹1.34 Cr | ₹2.28 Cr | ₹1.41 Cr | ₹16.4 Lakh | ₹26.8 Lakh | ₹1.83 Cr |
| Other Comprehensive Income | -₹2.33 Cr | ₹5.9 Lakh | -₹3.3 Lakh | ₹1.63 Cr | ₹82.1 Lakh | -₹1.58 Cr | ₹2.05 Cr |
| Total Comprehensive Income | ₹55.16 Cr | ₹28.89 Cr | ₹21.13 Cr | ₹29.66 Cr | ₹40.31 Cr | ₹33.12 Cr | ₹33.05 Cr |
| EBITDA (computed) | ₹96.34 Cr | ₹64.98 Cr | ₹64.29 Cr | ₹65.76 Cr | ₹73.72 Cr | ₹73.34 Cr | ₹61.77 Cr |
| Basic EPS | ₹67.57 | ₹33.89 | ₹24.88 | ₹32.96 | ₹46.41 | ₹40.79 | ₹36.44 |
| Diluted EPS | ₹67.57 | ₹33.89 | ₹24.88 | ₹0.00 | ₹46.41 | ₹40.79 | ₹36.44 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹677.94 Cr | ₹653.39 Cr | ₹662.35 Cr | ₹669.97 Cr |
| Non-current Assets | ₹469.38 Cr | ₹458.21 Cr | ₹447.73 Cr | ₹442.37 Cr |
| Current Assets | ₹208.56 Cr | ₹195.17 Cr | ₹214.62 Cr | ₹227.59 Cr |
| Property, Plant & Equipment | ₹411.06 Cr | ₹232.68 Cr | ₹239.47 Cr | ₹258.9 Cr |
| Inventories | ₹72.53 Cr | ₹70.38 Cr | ₹75.58 Cr | ₹84.81 Cr |
| Trade Receivables | ₹95.36 Cr | ₹73.18 Cr | ₹78.65 Cr | ₹79.63 Cr |
| Cash & Equivalents | ₹2.77 Cr | ₹5.59 Cr | ₹12.75 Cr | ₹13.16 Cr |
| Equity (Net Worth) | ₹367.79 Cr | ₹326.66 Cr | ₹302.88 Cr | ₹288.55 Cr |
| Equity Share Capital | ₹8.51 Cr | ₹8.51 Cr | ₹8.51 Cr | ₹8.51 Cr |
| Borrowings (Non-current) | ₹89.96 Cr | ₹133.37 Cr | ₹181.77 Cr | ₹184.85 Cr |
| Borrowings (Current) | ₹98.29 Cr | ₹74.41 Cr | ₹57.27 Cr | ₹83.3 Cr |
| Total Debt (computed) | ₹188.26 Cr | ₹207.78 Cr | ₹239.04 Cr | ₹268.15 Cr |
| Current Liabilities | ₹152.48 Cr | ₹125.18 Cr | ₹105.79 Cr | ₹148.7 Cr |
| Total Liabilities | ₹310.15 Cr | ₹326.73 Cr | ₹359.47 Cr | ₹381.42 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹64.14 Cr | ₹64.51 Cr | ₹48.13 Cr | ₹23.6 Cr | ₹8.81 Cr |
| Investing Cash Flow | -₹3.29 Cr | -₹19 Cr | -₹22.65 Cr | -₹77 Cr | -₹116.59 Cr |
| Financing Cash Flow | -₹48.79 Cr | -₹51.72 Cr | -₹26.05 Cr | ₹41.76 Cr | ₹111.61 Cr |
| Capital Expenditure | ₹17.83 Cr | ₹20.59 Cr | ₹24.4 Cr | ₹77.76 Cr | ₹95.71 Cr |
| Free Cash Flow (computed) | ₹46.31 Cr | ₹43.92 Cr | ₹23.74 Cr | -₹54.17 Cr | -₹86.9 Cr |
| Dividends Paid | ₹6.03 Cr | ₹5.17 Cr | ₹6.81 Cr | ₹8.51 Cr | ₹8.51 Cr |
| Net Change in Cash | -₹2.82 Cr | -₹6.72 Cr | -₹40.8 Lakh | -₹11.59 Cr | ₹3.48 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹100.11 Cr | ₹77.42 Cr | ₹70.97 Cr | ₹84.11 Cr | ₹81.93 Cr | ₹63.22 Cr | ₹83.69 Cr | ₹82.27 Cr | ₹79.26 Cr | ₹66.98 Cr | ₹70.46 Cr | ₹87.85 Cr |
| Other Income | -₹3.03 Cr | ₹66.9 Lakh | ₹9.73 Cr | ₹2.32 Cr | -₹6.95 Cr | ₹7.81 Cr | ₹1.84 Cr | ₹1.23 Cr | ₹4.15 Cr | ₹99 Lakh | ₹4.36 Cr | ₹1.15 Cr |
| Total Income | ₹97.08 Cr | ₹78.08 Cr | ₹80.7 Cr | ₹86.42 Cr | ₹74.98 Cr | ₹71.03 Cr | ₹85.53 Cr | ₹83.49 Cr | ₹83.4 Cr | ₹67.97 Cr | ₹74.81 Cr | ₹89 Cr |
| Cost of Materials Consumed | ₹21.3 Cr | ₹18.34 Cr | ₹17.43 Cr | ₹13.56 Cr | ₹15.56 Cr | ₹16.53 Cr | ₹15.91 Cr | ₹15.95 Cr | ₹14.47 Cr | ₹13.34 Cr | ₹14.29 Cr | ₹12.22 Cr |
| Purchases of Stock-in-Trade | ₹5.65 Cr | ₹5.65 Cr | -₹14.2 Lakh | ₹4.59 Cr | ₹4.7 Cr | ₹4.79 Cr | ₹3.02 Cr | ₹5.09 Cr | ₹6.41 Cr | ₹5.96 Cr | ₹6.02 Cr | ₹14.43 Cr |
| Changes in Inventories | -₹7.5 Cr | -₹3.26 Cr | ₹2.03 Cr | ₹4.32 Cr | ₹47.6 Lakh | -₹1.69 Cr | ₹5.6 Cr | ₹2.4 Cr | ₹66.3 Lakh | ₹1.34 Cr | -₹78.3 Lakh | ₹7.52 Cr |
| Employee Benefit Expense | ₹16.37 Cr | ₹15.52 Cr | ₹15.5 Cr | ₹15.28 Cr | ₹14.19 Cr | ₹16.34 Cr | ₹15.9 Cr | ₹16 Cr | ₹16.1 Cr | ₹15.58 Cr | ₹16.45 Cr | ₹16 Cr |
| Finance Costs | ₹5.1 Cr | ₹1.82 Cr | ₹2.21 Cr | ₹1.81 Cr | ₹5.62 Cr | -₹3.81 Cr | ₹5.89 Cr | ₹5.01 Cr | ₹6.94 Cr | ₹2.19 Cr | ₹8.08 Cr | ₹2.57 Cr |
| Depreciation & Amortisation | ₹5.91 Cr | ₹4.43 Cr | ₹4.35 Cr | ₹4.18 Cr | ₹4.18 Cr | ₹4.29 Cr | ₹4.2 Cr | ₹4.13 Cr | ₹3.74 Cr | ₹3.75 Cr | ₹4.28 Cr | ₹5.4 Cr |
| Other Expenses | ₹29.96 Cr | ₹23.38 Cr | ₹24.43 Cr | ₹23.55 Cr | ₹27.81 Cr | ₹22.19 Cr | ₹24.12 Cr | ₹25.18 Cr | ₹25.69 Cr | ₹20.61 Cr | ₹21.27 Cr | ₹23.32 Cr |
| Total Expenses | ₹76.79 Cr | ₹65.88 Cr | ₹65.81 Cr | ₹67.28 Cr | ₹72.54 Cr | ₹58.64 Cr | ₹74.62 Cr | ₹73.76 Cr | ₹74.01 Cr | ₹62.77 Cr | ₹69.6 Cr | ₹81.46 Cr |
| Profit Before Exceptional Items & Tax | ₹20.3 Cr | ₹12.21 Cr | ₹14.88 Cr | ₹19.14 Cr | ₹2.44 Cr | ₹12.39 Cr | ₹10.91 Cr | ₹9.73 Cr | ₹9.39 Cr | ₹5.2 Cr | ₹5.21 Cr | ₹7.54 Cr |
| Exceptional Items | ₹2.94 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹23.23 Cr | ₹12.21 Cr | ₹14.88 Cr | ₹19.14 Cr | ₹2.44 Cr | ₹12.39 Cr | ₹10.91 Cr | ₹9.73 Cr | ₹9.39 Cr | ₹5.2 Cr | ₹5.21 Cr | ₹7.54 Cr |
| Total Tax Expense | ₹8.54 Cr | ₹4.21 Cr | ₹2.71 Cr | ₹2.89 Cr | ₹2.2 Cr | ₹1.96 Cr | ₹3.48 Cr | ₹3.11 Cr | ₹3.47 Cr | ₹2.39 Cr | ₹2.72 Cr | ₹2.2 Cr |
| Net Profit | ₹16.55 Cr | ₹9.31 Cr | ₹14.33 Cr | ₹17.3 Cr | ₹1.54 Cr | ₹11.41 Cr | ₹8.39 Cr | ₹7.49 Cr | ₹6.4 Cr | ₹4.02 Cr | ₹4.04 Cr | ₹6.71 Cr |
| attributable to Owners | ₹15.98 Cr | ₹8.77 Cr | ₹14.45 Cr | ₹16.44 Cr | ₹1.29 Cr | ₹11.66 Cr | ₹8.2 Cr | ₹6.34 Cr | ₹4.95 Cr | ₹3.98 Cr | ₹4.09 Cr | ₹5.87 Cr |
| attributable to NCI | ₹56.4 Lakh | ₹54.5 Lakh | -₹11.8 Lakh | ₹85.4 Lakh | ₹25 Lakh | -₹25.4 Lakh | ₹19.2 Lakh | ₹1.15 Cr | ₹1.45 Cr | ₹3.6 Lakh | -₹4.5 Lakh | ₹84.1 Lakh |
| Other Comprehensive Income | -₹63.1 Lakh | -₹40.5 Lakh | -₹1.12 Cr | -₹17.6 Lakh | -₹17.2 Lakh | -₹36.9 Lakh | ₹20.9 Lakh | ₹39.1 Lakh | ₹1.15 Cr | -₹23.2 Lakh | -₹56.9 Lakh | -₹38.4 Lakh |
| Total Comprehensive Income | ₹15.92 Cr | ₹8.91 Cr | ₹13.22 Cr | ₹17.12 Cr | ₹1.37 Cr | ₹11.04 Cr | ₹8.6 Cr | ₹7.88 Cr | ₹7.55 Cr | ₹3.79 Cr | ₹3.47 Cr | ₹6.33 Cr |
| EBITDA (computed) | ₹31.3 Cr | ₹18.46 Cr | ₹21.45 Cr | ₹25.13 Cr | ₹12.23 Cr | ₹12.87 Cr | ₹21 Cr | ₹18.88 Cr | ₹20.07 Cr | ₹11.15 Cr | ₹17.57 Cr | ₹15.51 Cr |
| Basic EPS | ₹19.45 | ₹10.94 | ₹16.85 | ₹20.33 | ₹1.82 | ₹13.41 | ₹9.86 | ₹8.80 | ₹7.52 | ₹4.73 | ₹4.75 | ₹7.89 |
| Diluted EPS | ₹19.45 | ₹10.94 | ₹16.85 | ₹20.33 | ₹1.82 | ₹13.41 | ₹9.86 | ₹8.80 | ₹7.52 | ₹4.73 | ₹4.75 | ₹7.89 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Poultry Healthcare | ₹64.72 Cr | ₹23.11 Cr | ₹123.36 Cr | ₹15.8 Cr |
| Animal Healthcare | ₹35.39 Cr | ₹4.95 Cr | ₹225.39 Cr | ₹23.32 Cr |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Poultry Healthcare | ₹205.97 Cr | ₹58.09 Cr | - | - |
| Animal Healthcare | ₹126.63 Cr | ₹25.27 Cr | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹292.14 Cr | ₹286.47 Cr | ₹285.16 Cr | ₹254 Cr | ₹219.35 Cr | ₹208.48 Cr | ₹169.43 Cr |
| Other Income | ₹7.64 Cr | ₹4.76 Cr | ₹4.26 Cr | ₹5.32 Cr | ₹4.66 Cr | ₹1.65 Cr | ₹2.93 Cr |
| Total Income | ₹299.77 Cr | ₹291.23 Cr | ₹289.42 Cr | ₹259.32 Cr | ₹224.01 Cr | ₹210.13 Cr | ₹172.35 Cr |
| Cost of Materials Consumed | ₹46.22 Cr | ₹38.86 Cr | ₹32.69 Cr | ₹29.28 Cr | ₹34.93 Cr | ₹24.18 Cr | ₹21.13 Cr |
| Purchases of Stock-in-Trade | ₹39.44 Cr | ₹44.84 Cr | ₹56.6 Cr | ₹55.37 Cr | ₹39.3 Cr | ₹25.21 Cr | ₹17.19 Cr |
| Changes in Inventories | -₹3.69 Cr | ₹9.97 Cr | ₹10.36 Cr | -₹4.77 Cr | -₹12.53 Cr | ₹4.01 Cr | -₹15.57 Cr |
| Employee Benefit Expense | ₹53.17 Cr | ₹54.76 Cr | ₹56.72 Cr | ₹47.92 Cr | ₹39.12 Cr | ₹33.45 Cr | ₹37.16 Cr |
| Finance Costs | ₹7.17 Cr | ₹5.37 Cr | ₹5.09 Cr | ₹6.5 Cr | ₹2.47 Cr | ₹3.95 Cr | ₹5.03 Cr |
| Depreciation & Amortisation | ₹10.25 Cr | ₹8.58 Cr | ₹9.78 Cr | ₹9.79 Cr | ₹9.5 Cr | ₹9.63 Cr | ₹9.39 Cr |
| Other Expenses | ₹84.52 Cr | ₹87.1 Cr | ₹81.45 Cr | ₹71.32 Cr | ₹57.96 Cr | ₹49.64 Cr | ₹56.8 Cr |
| Total Expenses | ₹237.09 Cr | ₹249.47 Cr | ₹252.69 Cr | ₹215.4 Cr | ₹170.75 Cr | ₹150.06 Cr | ₹131.12 Cr |
| Profit Before Exceptional Items & Tax | ₹62.69 Cr | ₹41.76 Cr | ₹36.73 Cr | ₹43.92 Cr | ₹53.26 Cr | ₹60.06 Cr | ₹41.23 Cr |
| Exceptional Items | ₹7 Cr | ₹0 | ₹0 | ₹0 | ₹0 | -₹5.28 Cr | ₹0 |
| Profit Before Tax | ₹69.68 Cr | ₹41.76 Cr | ₹36.73 Cr | ₹43.92 Cr | ₹53.26 Cr | ₹54.78 Cr | ₹41.23 Cr |
| Total Tax Expense | ₹17.58 Cr | ₹9.92 Cr | ₹9.57 Cr | ₹11.58 Cr | ₹13.74 Cr | ₹14.88 Cr | ₹10 Cr |
| Net Profit | ₹52.1 Cr | ₹31.84 Cr | ₹27.16 Cr | ₹32.34 Cr | ₹39.52 Cr | ₹39.9 Cr | ₹31.22 Cr |
| Other Comprehensive Income | -₹5 Lakh | -₹36.3 Lakh | -₹2.4 Lakh | ₹11.3 Lakh | -₹15.7 Lakh | ₹21.4 Lakh | -₹40.1 Lakh |
| Total Comprehensive Income | ₹52.05 Cr | ₹31.48 Cr | ₹27.14 Cr | ₹32.46 Cr | ₹39.36 Cr | ₹40.12 Cr | ₹30.82 Cr |
| EBITDA (computed) | ₹80.11 Cr | ₹55.71 Cr | ₹51.6 Cr | ₹60.21 Cr | ₹65.23 Cr | ₹73.64 Cr | ₹55.65 Cr |
| Basic EPS | ₹61.24 | ₹37.43 | ₹31.93 | ₹38.02 | ₹46.45 | ₹46.90 | ₹36.70 |
| Diluted EPS | ₹61.24 | ₹37.43 | ₹31.93 | ₹38.02 | ₹46.45 | ₹46.90 | ₹36.70 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹557.35 Cr | ₹546 Cr | ₹549.55 Cr | ₹545.82 Cr |
| Non-current Assets | ₹367.58 Cr | ₹360.76 Cr | ₹345.13 Cr | ₹329.77 Cr |
| Current Assets | ₹189.76 Cr | ₹185.24 Cr | ₹204.41 Cr | ₹216.05 Cr |
| Property, Plant & Equipment | ₹287.61 Cr | ₹104.83 Cr | ₹102.89 Cr | ₹107.85 Cr |
| Inventories | ₹59.98 Cr | ₹58.51 Cr | ₹68.53 Cr | ₹79.22 Cr |
| Trade Receivables | ₹92.04 Cr | ₹80.6 Cr | ₹85.78 Cr | ₹82.36 Cr |
| Cash & Equivalents | ₹79 Lakh | ₹54.5 Lakh | ₹2.41 Cr | ₹4.3 Cr |
| Equity (Net Worth) | ₹385.18 Cr | ₹339.09 Cr | ₹312.71 Cr | ₹292.38 Cr |
| Equity Share Capital | ₹8.51 Cr | ₹8.51 Cr | ₹8.51 Cr | ₹8.51 Cr |
| Borrowings (Non-current) | ₹21.68 Cr | ₹51.31 Cr | ₹79.07 Cr | ₹83.4 Cr |
| Borrowings (Current) | ₹52.79 Cr | ₹52.96 Cr | ₹54.49 Cr | ₹80.93 Cr |
| Total Debt (computed) | ₹74.47 Cr | ₹104.27 Cr | ₹133.56 Cr | ₹164.32 Cr |
| Current Liabilities | ₹91.92 Cr | ₹96.7 Cr | ₹97.72 Cr | ₹136.47 Cr |
| Total Liabilities | ₹172.16 Cr | ₹206.91 Cr | ₹236.83 Cr | ₹253.43 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹50.92 Cr | ₹63.97 Cr | ₹42.81 Cr | ₹33.36 Cr | ₹15.91 Cr |
| Investing Cash Flow | -₹2.36 Cr | -₹19.04 Cr | -₹20.63 Cr | -₹71.96 Cr | -₹110.58 Cr |
| Financing Cash Flow | -₹48.31 Cr | -₹46.35 Cr | -₹24.07 Cr | ₹41.38 Cr | ₹94.96 Cr |
| Capital Expenditure | ₹17.33 Cr | ₹20.63 Cr | ₹22.38 Cr | ₹72.64 Cr | ₹90.67 Cr |
| Free Cash Flow (computed) | ₹33.6 Cr | ₹43.34 Cr | ₹20.44 Cr | -₹39.28 Cr | -₹74.76 Cr |
| Dividends Paid | ₹6.03 Cr | ₹5.17 Cr | ₹6.81 Cr | ₹8.51 Cr | ₹8.51 Cr |
| Net Change in Cash | ₹24.5 Lakh | -₹1.42 Cr | -₹1.89 Cr | ₹2.77 Cr | ₹28.4 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹93.71 Cr | ₹70.35 Cr | ₹64.58 Cr | ₹63.49 Cr | ₹76.67 Cr | ₹62.83 Cr | ₹73.5 Cr | ₹73.47 Cr | ₹72.87 Cr | ₹65.51 Cr | ₹66.43 Cr | ₹80.35 Cr |
| Other Income | ₹4.18 Cr | ₹1.04 Cr | ₹1.48 Cr | ₹94.6 Lakh | ₹1.06 Cr | ₹1.3 Cr | ₹1.35 Cr | ₹1.06 Cr | ₹1.2 Cr | ₹98 Lakh | ₹1.22 Cr | ₹85.9 Lakh |
| Total Income | ₹97.89 Cr | ₹71.39 Cr | ₹66.05 Cr | ₹64.44 Cr | ₹77.73 Cr | ₹64.13 Cr | ₹74.85 Cr | ₹74.52 Cr | ₹74.08 Cr | ₹66.49 Cr | ₹67.65 Cr | ₹81.2 Cr |
| Cost of Materials Consumed | ₹16.51 Cr | ₹11.31 Cr | ₹9.72 Cr | ₹8.68 Cr | ₹9.02 Cr | ₹8.44 Cr | ₹10.81 Cr | ₹10.59 Cr | ₹9.17 Cr | ₹6.65 Cr | ₹8.43 Cr | ₹8.43 Cr |
| Purchases of Stock-in-Trade | ₹9.83 Cr | ₹12.84 Cr | ₹7.84 Cr | ₹8.93 Cr | ₹13.64 Cr | ₹12.01 Cr | ₹9.26 Cr | ₹9.93 Cr | ₹13.59 Cr | ₹13.57 Cr | ₹11.68 Cr | ₹17.75 Cr |
| Changes in Inventories | -₹6 Cr | -₹2.78 Cr | ₹3.21 Cr | ₹1.87 Cr | ₹3.28 Cr | -₹27.2 Lakh | ₹4.52 Cr | ₹2.44 Cr | ₹51.4 Lakh | ₹1.43 Cr | ₹25.8 Lakh | ₹8.16 Cr |
| Employee Benefit Expense | ₹14 Cr | ₹12.91 Cr | ₹13.02 Cr | ₹13.25 Cr | ₹12.14 Cr | ₹14.31 Cr | ₹14.11 Cr | ₹14.21 Cr | ₹14.32 Cr | ₹13.61 Cr | ₹14.66 Cr | ₹14.13 Cr |
| Finance Costs | ₹4.09 Cr | ₹89.8 Lakh | ₹1.27 Cr | ₹90.5 Lakh | ₹1.25 Cr | ₹1.59 Cr | ₹1.4 Cr | ₹1.13 Cr | ₹1.31 Cr | ₹1.37 Cr | ₹1.48 Cr | ₹94.2 Lakh |
| Depreciation & Amortisation | ₹3.68 Cr | ₹2.21 Cr | ₹2.2 Cr | ₹2.16 Cr | ₹2.03 Cr | ₹2.24 Cr | ₹2.19 Cr | ₹2.12 Cr | ₹2.08 Cr | ₹2.57 Cr | ₹2.58 Cr | ₹2.55 Cr |
| Other Expenses | ₹27.9 Cr | ₹19.35 Cr | ₹18.92 Cr | ₹18.35 Cr | ₹24.89 Cr | ₹19.32 Cr | ₹20.08 Cr | ₹22.81 Cr | ₹22.86 Cr | ₹18.67 Cr | ₹19.41 Cr | ₹20.51 Cr |
| Total Expenses | ₹70.02 Cr | ₹56.75 Cr | ₹56.17 Cr | ₹54.15 Cr | ₹66.25 Cr | ₹57.64 Cr | ₹62.37 Cr | ₹63.22 Cr | ₹63.85 Cr | ₹57.87 Cr | ₹58.49 Cr | ₹72.47 Cr |
| Profit Before Exceptional Items & Tax | ₹27.87 Cr | ₹14.64 Cr | ₹9.88 Cr | ₹10.29 Cr | ₹11.48 Cr | ₹6.49 Cr | ₹12.48 Cr | ₹11.31 Cr | ₹10.23 Cr | ₹8.61 Cr | ₹9.16 Cr | ₹8.73 Cr |
| Exceptional Items | ₹7 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹34.87 Cr | ₹14.64 Cr | ₹9.88 Cr | ₹10.29 Cr | ₹11.48 Cr | ₹6.49 Cr | ₹12.48 Cr | ₹11.31 Cr | ₹10.23 Cr | ₹8.61 Cr | ₹9.16 Cr | ₹8.73 Cr |
| Total Tax Expense | ₹8.49 Cr | ₹3.97 Cr | ₹2.67 Cr | ₹2.45 Cr | ₹1.85 Cr | ₹2.05 Cr | ₹3.15 Cr | ₹2.87 Cr | ₹2.79 Cr | ₹2.14 Cr | ₹2.38 Cr | ₹2.26 Cr |
| Net Profit | ₹26.38 Cr | ₹10.67 Cr | ₹7.21 Cr | ₹7.84 Cr | ₹9.64 Cr | ₹4.44 Cr | ₹9.34 Cr | ₹8.43 Cr | ₹7.43 Cr | ₹6.48 Cr | ₹6.78 Cr | ₹6.47 Cr |
| Other Comprehensive Income | -₹5 Lakh | ₹18.2 Lakh | -₹9.2 Lakh | -₹9 Lakh | -₹34.5 Lakh | -₹60,000 | -₹60,000 | -₹60,000 | -₹10.9 Lakh | ₹2.9 Lakh | ₹2.7 Lakh | ₹2.9 Lakh |
| Total Comprehensive Income | ₹26.33 Cr | ₹10.85 Cr | ₹7.12 Cr | ₹7.75 Cr | ₹9.29 Cr | ₹4.43 Cr | ₹9.33 Cr | ₹8.43 Cr | ₹7.32 Cr | ₹6.5 Cr | ₹6.81 Cr | ₹6.5 Cr |
| EBITDA (computed) | ₹35.64 Cr | ₹17.75 Cr | ₹13.36 Cr | ₹13.36 Cr | ₹14.76 Cr | ₹10.32 Cr | ₹16.08 Cr | ₹14.55 Cr | ₹13.62 Cr | ₹12.55 Cr | ₹13.21 Cr | ₹12.22 Cr |
| Basic EPS | ₹31.01 | ₹12.54 | ₹8.48 | ₹9.21 | ₹11.33 | ₹5.22 | ₹10.97 | ₹9.91 | ₹8.74 | ₹7.61 | ₹7.97 | ₹7.61 |
| Diluted EPS | ₹31.01 | ₹12.54 | ₹8.48 | ₹9.21 | ₹11.33 | ₹5.22 | ₹10.97 | ₹9.91 | ₹8.74 | ₹7.61 | ₹7.97 | ₹7.61 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Poultry Healthcare | ₹65.07 Cr | ₹23.52 Cr | ₹122.99 Cr | ₹15.67 Cr |
| Animal Healthcare | ₹28.64 Cr | ₹10.2 Cr | ₹67.98 Cr | ₹10.05 Cr |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Poultry Healthcare | ₹206.13 Cr | ₹58.14 Cr | - | - |
| Animal Healthcare | ₹86.01 Cr | ₹16.39 Cr | - | - |
Board & Governance of Hester Biosciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-DEC-2025, the board of Hester Biosciences Limited has 11 directors - 5 independent and 2 executive. The board is chaired by Bhupendra Vittaldas Gandhi.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Bhupendra Vittaldas Gandhi | Non-Executive - Non Independent Director · Chairperson | 2005-04-21 | 1 |
| Rajiv Dinesh Gandhi | Executive Director · CEO-MD | 1987-04-29 | 2 |
| Sanjiv Dinesh Gandhi | Non-Executive - Non Independent Director | 1987-04-29 | 1 |
| Ravin Kanti Gandhi | Non-Executive - Non Independent Director | 1999-04-22 | 1 |
| Nina Rajiv Gandhi | Alternate Director | 2016-05-07 | 1 |
| Priya Gandhi | Executive Director | 2021-10-28 | 1 |
| Sandhya Maulik Patel | Non-Executive - Independent Director · Shareholder Director | 2020-04-01 | 1 |
| Ashok Bhhimarao Bhadakal | Non-Executive - Independent Director · Shareholder Director | 2020-04-01 | 1 |
| Ameet Hiranyakumar Desai | Non-Executive - Independent Director · Shareholder Director | 2021-10-28 | 4 |
| Jatin Trivedi | Non-Executive - Independent Director · Shareholder Director | 2023-06-26 | 1 |
| Anil Jain | Non-Executive - Independent Director · Shareholder Director | 2023-06-26 | 2 |
| Committee | Members |
|---|---|
| Audit Committee | Ashok Bhadakal (Chairperson), Sandhya Patel, Priya Gandhi |
| Nomination and remuneration committee | Ashok Bhadakal (Chairperson), Sandhya Patel, Sanjiv Gandhi |
| Stakeholders Relationship Committee | Sandhya Patel (Chairperson), Rajiv Gandhi, Priya Gandhi |
| Risk Management Committee | Rajiv Gandhi (Chairperson), Sandhya Patel, Priya Gandhi |
| Corporate Social Responsibility Committee | Rajiv Gandhi (Chairperson), Sanjiv Gandhi, Sandhya Patel |
Charges & Borrowings of Hester Biosciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Dec 2021 | State Bank of India | ₹91.08 Cr | Open |
| 28 Dec 2013 | State Bank of India | ₹110.97 Cr | Open |
| 15 Apr 2020 | State Bank of India | ₹5 Cr | Satisfied |
| 16 Oct 2019 | Hdfc Bank Limited | ₹37.7 Lakh | Satisfied |
| 26 Jul 2019 | Axis Bank Limited | ₹55.27 Lakh | Satisfied |
Total charge records: 30 View all charges
Employees and EPFO Compliance at Hester Biosciences Limited
View historical data on people associated with Hester Biosciences Limited, including employment history and EPFO contributions.
Employee and EPFO history for Hester Biosciences Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Hester Biosciences Limited
GST registrations and filing compliance for Hester Biosciences Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Hester Biosciences Limited
Credit ratings, litigation, and regulatory alerts for Hester Biosciences Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Hester Biosciences Limited
MSME payment history for Hester Biosciences Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Hester Biosciences Limited
Corporate group structure for Hester Biosciences Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Hester Biosciences Limited
MCA filings and documents for Hester Biosciences Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Hester Biosciences Limited
Recent News on Hester Biosciences Limited
Frequently Asked Questions about Hester Biosciences Limited
Hester Biosciences Limited is an active public limited company in the pharma sector based in Mahesana, Gujarat, India. It was incorporated on 29 April 1987 (39+ years old) and is registered under CIN L99999GJ1987PLC022333. Listed on BSE: 524669 and NSE: HESTERBIO. The company has 695 employees.
Hester Biosciences Limited reported revenue of ₹332.6 Cr for FY 2026 (up 6.91% YoY) based on consolidated NSE filings.
The current directors of Hester Biosciences Limited are:
- Sanjiv Dinesh Gandhi - Director
- Bhupendra Vithaldas Gandhi - Director
- Ravin Kanti Gandhi - Director
- Rajiv Gandhi - Managing Director
- Nina Rajiv Gandhi - Alternate Director
- Ashok Bhadakal Bhimarao - Director
- Priya Rajiv Gandhi - Whole-Time Director
- Ameetkumar Hiranyakumar Desai - Director
- Sandhya Maulik Patel - Director
- Anil Jain - Director
- Jatin Yagneshbhai Trivedi - Director
The primary industry of Hester Biosciences Limited is pharma. The company specifically operates in animal pharmaceuticals and healthcare. The company is currently active in this sector.
Yes. Hester Biosciences Limited is listed on both BSE (code: 524669) and NSE (symbol: HESTERBIO).
Hester Biosciences Limited can be reached at the registered office: Village Meda – Adraj, Taluka Kadi, Mahesana, Gujarat, India – 384441, or through the website hester.in.